Skip to main content

Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan

International Journal of Hematology volume 88, pages 291–293 (2008)Cite this article

Abstract

We report the case of a 58-year-old man with multiple myeloma stage III A who received tandem autologous stem cell transplantation after induction by two courses of VAD and three cycles of bortezomib–dexamethasone, due to progression under chemotherapy. The second transplantation was complicated by severe hepatic veno-occlusive disease (HVOD). The patient received defibrotide with total recovery. The occurence of HVOD after conditioning by melphalan is uncommon and the role of bortezomib was questioned.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003;10:451–62.

    Article  PubMed  Google Scholar 

  2. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502.

    CAS  Article  PubMed  Google Scholar 

  3. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99:731–2.

    CAS  Article  PubMed  Google Scholar 

  4. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt P, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–43.

    CAS  Article  PubMed  Google Scholar 

  5. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005–20.

    CAS  PubMed  Google Scholar 

  6. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67.

    CAS  Article  PubMed  Google Scholar 

  7. Alegre A, Diaz-Mediavilla J, San-Miguel J, Martinez R, Garcia-Larana J, Sureda A, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant. 1998;21:133–40.

    CAS  Article  PubMed  Google Scholar 

  8. Malhorta P, Varma S, Varma N, Sharma RR, Jain S, Kumari S, et al. Pulmonary veno-occlusive disease as a cause for reversible pulmonary hypertension in a patient with multiple myeloma undergoing peripheral blood stem cell transplantation. Am J Hematol. 2005;80:164–5.

    Google Scholar 

  9. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Iwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.

    CAS  Article  PubMed  Google Scholar 

  10. Harousseau JL, Attal M, Leleu X, Troncy J, Pegouie P, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91:1498–505.

    CAS  PubMed  Google Scholar 

  11. Rosinol L, Oriol A, Mateos MV, Sureda A, Garcia-Sanchez P, Gutierrez N, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol. 2007;25:4452–8.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France

    Sana Intidhar Labidi, Catherine Sebban, Hervé Ghesquières, Emmanuele Virelizier Nicolas & Pierre Biron

Authors
  1. Sana Intidhar Labidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Sebban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hervé Ghesquières
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuele Virelizier Nicolas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pierre Biron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sana Intidhar Labidi.

About this article

Cite this article

Labidi, S.I., Sebban, C., Ghesquières, H. et al. Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan. Int J Hematol 88, 291–293 (2008). https://doi.org/10.1007/s12185-008-0152-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0152-x

Keywords

  • Bortezomib
  • Multiple myeloma
  • Autologous stem cell transplantation
  • Defibrotide